Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START SYNERGY: ELV001 dose-ranging add-on study in active rheumatoid arthritis
NL-OMON61174Phase 2Not yet recruiting
- Sponsor
- Elevara Medicines
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ELV001 in rheumatoid arthritis (RA), sponsored by Elevara Medicines. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
ELV001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON61174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61174.